Reviva Pharmaceuticals Holdings, Inc.
RVPH
$0.35
-$0.44-55.73%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 46.20% | 52.06% | 22.98% | 13.46% | 33.09% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -27.37% | 76.35% | 142.09% | 1,084.96% | 74.58% |
| Change in Net Operating Assets | 16.60% | -153.65% | 184.74% | 37.71% | -2,297.68% |
| Cash from Operations | 36.29% | -31.78% | 40.86% | 30.12% | -2.52% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -27.58% | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | 9.08% | 10.76% | -181.81% | 16.04% |
| Issuance of Common Stock | -60.06% | 127.47% | 263.54% | -- | -39.47% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -58.55% | 132.16% | 276.29% | -97.80% | -37.60% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -84.14% | 555.20% | 187.56% | 28.15% | -56.96% |